Targacept Inc. (TRGT) announced top-line results from two separate exploratory Phase 2 studies of its product candidate TC-6987 conducted in the U.S., one in asthma and one in type 2 diabetes.
In the asthma study, oral TC-6987 met protocol-defined success criteria on both co-primary outcome measures, change from baseline in forced expiratory volume for adjunct TC-6987 compared to adjunct placebo measured at two time points on day 28. In the type 2 diabetes study, the primary outcome measure, change in fasting plasma glucose, was not met, and Targacept would not pursue further development of TC-6987 as a treatment for diabetes.
TC-6987 is a modulator of the alpha7 neuronal nicotinic receptor discovered by Targacept scientists using Pentad, the company's proprietary drug discovery platform.
For comments and feedback: editorial@rttnews.com